{"DataElement":{"publicId":"3297530","version":"1","preferredName":"Tumor Stage Grouping Ovarian Carcinoma Stage","preferredDefinition":"A description of the stage of the ovarian carcinoma.","longName":"2014085v1.0:3297519v1.0","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"2014085","version":"1","preferredName":"Tumor Stage Grouping","preferredDefinition":"information related to the stage grouping for a tumor.","longName":"TUMOR_GP","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2176931","version":"1","preferredName":"Tumor","preferredDefinition":"An abnormal tissue growth resulted from uncontrolled cell proliferation.  Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant ones exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia.  Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias. -- 2004","longName":"Tumor","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Neoplasm","conceptCode":"C3262","definition":"A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"ACAAECCE-7B01-657B-E034-0003BA0B1A09","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-04-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2230143","version":"1","preferredName":"Stage Grouping","preferredDefinition":"Stage Grouping; an assessment based on the combined evaluation of the patient's T stage, M stage, and N stage. (caDSR)","longName":"C38027","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage Grouping","conceptCode":"C38027","definition":"An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F752037A-4CC2-36A8-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-05-18","modifiedBy":"ONEDATA","dateModified":"2005-05-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B4AE39F7-71FA-418C-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-01-20","endDate":null,"createdBy":"MWHITE","dateCreated":"2003-01-20","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3297519","version":"1","preferredName":"Ovarian Carcinoma Stage","preferredDefinition":"A malignant neoplasm originating from the surface ovarian epithelium.  It accounts for the greatest number of deaths from malignancies of the female genital tract and is the fifth leading cause of cancer fatalities in women.  It is predominantly a disease of older white women of northern European extraction, but it is seen in all ages and ethnic groups.  Adenocarcinomas constitute the vast majority of ovarian carcinomas.  The pattern of metastatic spread in ovarian carcinoma is similar regardless of the microscopic type.  The most common sites of involvement are the contralateral ovary, peritoneal cavity, para-aortic and pelvic lymph nodes, and liver.  Lung and pleura are the most common sites of extra-abdominal spread.  The primary form of therapy is surgical.  The overall prognosis of ovarian carcinoma remains poor, a direct result of its rapid growth rate and the lack of early symptoms. --2002_The extent of a cancer within the body, especially whether the disease has spread from the original site to other parts of the body.","longName":"3297519v1.0","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"60","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Stage unknown","valueDescription":"Stage unknown","ValueMeaning":{"publicId":"2876579","version":"1","preferredName":"Stage unknown","longName":"2876579","preferredDefinition":"The extent of a cancer within the body, especially whether the disease has spread from the original site to other parts of the body.: Not known, not observed, not recorded, or refused.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neoplasm Stage","conceptCode":"C16899","definition":"The extent of a cancer in the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"69E48D41-7CF3-7F3B-E040-BB89AD4305C2","latestVersionIndicator":"Yes","beginDate":"2009-05-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-05-14","modifiedBy":"CURTIST","dateModified":"2009-05-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B022AE88-96AF-4BBE-E040-BB89AD4361BF","beginDate":"2011-10-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-10-25","modifiedBy":"ONEDATA","dateModified":"2011-10-25","deletedIndicator":"No"},{"value":"IV","valueDescription":"IV","ValueMeaning":{"publicId":"3297520","version":"1","preferredName":"IV","longName":"3297520","preferredDefinition":"Growth involving one or both ovaries with distant metastases; if pleural effusion is present, there must be positive cytologic test results to allot a case to stage IV; parenchymal liver metastasis equals stage IV.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B022AE88-96B9-4BBE-E040-BB89AD4361BF","latestVersionIndicator":"Yes","beginDate":"2011-10-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-10-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B022AE88-96D2-4BBE-E040-BB89AD4361BF","beginDate":"2011-10-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-10-25","modifiedBy":"ONEDATA","dateModified":"2011-10-25","deletedIndicator":"No"},{"value":"IIIC","valueDescription":"IIIC","ValueMeaning":{"publicId":"3297521","version":"1","preferredName":"IIIC","longName":"3297521","preferredDefinition":"Abdominal implants greater than 2 cm in diameter and/or positive retroperitoneal or inguinal nodes.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B022AE88-96DC-4BBE-E040-BB89AD4361BF","latestVersionIndicator":"Yes","beginDate":"2011-10-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-10-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B022AE88-96F5-4BBE-E040-BB89AD4361BF","beginDate":"2011-10-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-10-25","modifiedBy":"ONEDATA","dateModified":"2011-10-25","deletedIndicator":"No"},{"value":"IIIB","valueDescription":"IIIB","ValueMeaning":{"publicId":"3297522","version":"1","preferredName":"IIIB","longName":"3297522","preferredDefinition":"Tumor of one or both ovaries; histologically confirmed implants of abdominal peritoneal surfaces, none greater than 2 cm in diameter; node negative.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B022AE88-96FF-4BBE-E040-BB89AD4361BF","latestVersionIndicator":"Yes","beginDate":"2011-10-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-10-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B022AE88-9718-4BBE-E040-BB89AD4361BF","beginDate":"2011-10-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-10-25","modifiedBy":"ONEDATA","dateModified":"2011-10-25","deletedIndicator":"No"},{"value":"IIC","valueDescription":"IIC","ValueMeaning":{"publicId":"3297524","version":"1","preferredName":"IIC","longName":"3297524","preferredDefinition":"Either stage IIA or IIB tumor on the surface of one or both ovaries; capsule(s) ruptured; ascites present containing malignant cells; or positive peritoneal washings.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B022AE88-9745-4BBE-E040-BB89AD4361BF","latestVersionIndicator":"Yes","beginDate":"2011-10-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-10-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B022AE88-975E-4BBE-E040-BB89AD4361BF","beginDate":"2011-10-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-10-25","modifiedBy":"ONEDATA","dateModified":"2011-10-25","deletedIndicator":"No"},{"value":"IIB","valueDescription":"IIB","ValueMeaning":{"publicId":"3297525","version":"1","preferredName":"IIB","longName":"3297525","preferredDefinition":"Extension to other pelvic tissues.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B022AE88-9768-4BBE-E040-BB89AD4361BF","latestVersionIndicator":"Yes","beginDate":"2011-10-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-10-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B022AE88-9781-4BBE-E040-BB89AD4361BF","beginDate":"2011-10-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-10-25","modifiedBy":"ONEDATA","dateModified":"2011-10-25","deletedIndicator":"No"},{"value":"IIA","valueDescription":"IIA","ValueMeaning":{"publicId":"3297526","version":"1","preferredName":"IIA","longName":"3297526","preferredDefinition":"Extension and/or metastases to the uterus and/or fallopian tubes.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B022AE88-978B-4BBE-E040-BB89AD4361BF","latestVersionIndicator":"Yes","beginDate":"2011-10-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-10-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B022AE88-97A4-4BBE-E040-BB89AD4361BF","beginDate":"2011-10-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-10-25","modifiedBy":"ONEDATA","dateModified":"2011-10-25","deletedIndicator":"No"},{"value":"IB","valueDescription":"IB","ValueMeaning":{"publicId":"3297528","version":"1","preferredName":"IB","longName":"3297528","preferredDefinition":"Growth limited to both ovaries; no ascites; no tumor on the external surfaces, capsule intact.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B022AE88-97D1-4BBE-E040-BB89AD4361BF","latestVersionIndicator":"Yes","beginDate":"2011-10-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-10-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B022AE88-97EA-4BBE-E040-BB89AD4361BF","beginDate":"2011-10-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-10-25","modifiedBy":"ONEDATA","dateModified":"2011-10-25","deletedIndicator":"No"},{"value":"In situ","valueDescription":"In situ","ValueMeaning":{"publicId":"2558929","version":"1","preferredName":"In situ","longName":"2558929","preferredDefinition":"in the natural or normal place, confined to the site of origin without invasion of neighboring tissues. (On-line Medical Dictionary)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"In Situ","conceptCode":"C14160","definition":"In the natural or normal place, confined to the site of origin without invasion of neighboring tissues.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B33E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CURTIST","dateModified":"2009-05-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B022AE88-9817-4BBE-E040-BB89AD4361BF","beginDate":"2011-10-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-10-25","modifiedBy":"ONEDATA","dateModified":"2011-10-25","deletedIndicator":"No"},{"value":"IA","valueDescription":"IA","ValueMeaning":{"publicId":"3309137","version":"1","preferredName":"IA","longName":"3309137","preferredDefinition":"Growth limited to one ovary; no ascites; no tumor on the external surfaces, capsule intact.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B26C38EE-DA0E-3EAD-E040-BB89AD435021","latestVersionIndicator":"Yes","beginDate":"2011-11-23","endDate":null,"createdBy":"NYCHM","dateCreated":"2011-11-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B26C38EE-DA26-3EAD-E040-BB89AD435021","beginDate":"2011-10-25","endDate":null,"createdBy":"NYCHM","dateCreated":"2011-11-23","modifiedBy":"ONEDATA","dateModified":"2011-11-23","deletedIndicator":"No"},{"value":"IIIA","valueDescription":"IIIA","ValueMeaning":{"publicId":"3309138","version":"1","preferredName":"IIIA","longName":"3309138","preferredDefinition":"Tumor grossly limited to the true pelvis with negative nodes but with histologically confirmed microscopic seeding of abdominal peritoneal surfaces.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B26C38EE-DA30-3EAD-E040-BB89AD435021","latestVersionIndicator":"Yes","beginDate":"2011-11-23","endDate":null,"createdBy":"NYCHM","dateCreated":"2011-11-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B26C38EE-DA48-3EAD-E040-BB89AD435021","beginDate":"2011-10-25","endDate":null,"createdBy":"NYCHM","dateCreated":"2011-11-23","modifiedBy":"ONEDATA","dateModified":"2011-11-23","deletedIndicator":"No"},{"value":"IC","valueDescription":"IC","ValueMeaning":{"publicId":"3334983","version":"1","preferredName":"IC","longName":"3334983","preferredDefinition":"Either stage IA or IB tumor on the surface of one or both ovaries; capsule ruptured; ascites present containing malignant cells; or positive peritoneal washings.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B4392D5E-AF2F-E896-E040-BB89AD432A32","latestVersionIndicator":"Yes","beginDate":"2011-12-16","endDate":null,"createdBy":"ZHANGW","dateCreated":"2011-12-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B4392D5E-AF47-E896-E040-BB89AD432A32","beginDate":"2011-10-25","endDate":null,"createdBy":"ZHANGW","dateCreated":"2011-12-16","modifiedBy":"ONEDATA","dateModified":"2011-12-16","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2435022","version":"1","preferredName":"Disease, Disorder or Finding","preferredDefinition":"Specification of human conditions relevant to cancer. This includes observations, test results, history, and other concepts relevant to characterization of human cancer-related conditions. Non-neoplastic conditions of interest are also included.","longName":"C7057","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B16D-87D9-26CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3297518","version":"1","preferredName":"Ovarian Carcinoma Stage","preferredDefinition":"A malignant neoplasm originating from the surface ovarian epithelium.  It accounts for the greatest number of deaths from malignancies of the female genital tract and is the fifth leading cause of cancer fatalities in women.  It is predominantly a disease of older white women of northern European extraction, but it is seen in all ages and ethnic groups.  Adenocarcinomas constitute the vast majority of ovarian carcinomas.  The pattern of metastatic spread in ovarian carcinoma is similar regardless of the microscopic type.  The most common sites of involvement are the contralateral ovary, peritoneal cavity, para-aortic and pelvic lymph nodes, and liver.  Lung and pleura are the most common sites of extra-abdominal spread.  The primary form of therapy is surgical.  The overall prognosis of ovarian carcinoma remains poor, a direct result of its rapid growth rate and the lack of early symptoms. --2002:The extent of a cancer within the body, especially whether the disease has spread from the original site to other parts of the body.","longName":"C4908:C16899","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ovarian Carcinoma","conceptCode":"C4908","definition":"A malignant neoplasm originating from the surface ovarian epithelium.  It accounts for the greatest number of deaths from malignancies of the female genital tract and is the fifth leading cause of cancer fatalities in women.  It is predominantly a disease of older white women of northern European extraction, but it is seen in all ages and ethnic groups.  Adenocarcinomas constitute the vast majority of ovarian carcinomas.  The pattern of metastatic spread in ovarian carcinoma is similar regardless of the microscopic type.  The most common sites of involvement are the contralateral ovary, peritoneal cavity, para-aortic and pelvic lymph nodes, and liver.  Lung and pleura are the most common sites of extra-abdominal spread.  The primary form of therapy is surgical.  The overall prognosis of ovarian carcinoma remains poor, a direct result of its rapid growth rate and the lack of early symptoms.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Neoplasm Stage","conceptCode":"C16899","definition":"The extent of a cancer in the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B022AE88-967E-4BBE-E040-BB89AD4361BF","latestVersionIndicator":"Yes","beginDate":"2011-10-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-10-25","modifiedBy":"ONEDATA","dateModified":"2011-10-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B022AE88-968F-4BBE-E040-BB89AD4361BF","latestVersionIndicator":"Yes","beginDate":"2011-10-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-10-25","modifiedBy":"KUMMEROA","dateModified":"2021-06-25","changeDescription":". 2021-6-25 ak Released per Janet review.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[{"name":"oc_base_dx_stage_diag_kn","type":"NMDP_FN","context":"NHLBI"}],"ReferenceDocuments":[{"name":"What was the stage of ovarian","type":"Preferred Question Text","description":"What was the stage of ovarian cancer?","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B022AE88-9828-4BBE-E040-BB89AD4361BF","latestVersionIndicator":"Yes","beginDate":"2011-10-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-10-25","modifiedBy":"KUMMEROA","dateModified":"2021-06-25","changeDescription":". 2021-6-25 ak Released per Janet review. System generated def displayed as alt def.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}